Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Director dealing

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests has been notified that on 5 June 2014, Andy Blackwell, Chief Scientific Officer, sold 150,000 Ordinary Shares at a price of 80 pence each. Following this notification, Mr Blackwell now has a total beneficial interest of 131,095 Ordinary Shares representing 0.77% of the issued share capital of the Company

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.